Skip to content

Study · Not a test of the peptide alone · 2011

6 results

Human embryonic stem cell-derived microvascular grafts for cardiac tissue preservation after myocardial infarction.

Kraehenbuehl TP, Ferreira LS, Hayward AM, Nahrendorf M, van der Vlies AJ, Vasile E, Weissleder R, Langer R, Hubbell JA

Biomaterials28 Oct 2010Cited by 87 (Europe PMC)

PMID21035182 (opens in a new tab)PMCIDPMC6805145 (opens in a new tab)DOI10.1016/j.biomaterials.2010.10.005 (opens in a new tab)PepBankPUB-21035182
Source linkPubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone6

In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Thymosin beta-4 (human).

  1. 01AnimalNot a test of Thymosin beta-4 (human) aloneAnimal study (in vivo)Efficacy outcome

    In rats with myocardial infarction, microvascular grafts (hydrogel with thymosin beta‑4 and hESC-derived vascular cells) raised ejection fraction by about 7% at 3 days versus PBS.

    In plain wordsIn rats with a heart attack, a gel with thymosin beta‑4 and human stem cell-derived cells improved heart pumping versus PBS at 3 days.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    IncreaseEjection fraction at 3 days
    Study

    ratn: not reported in source

    rat model of myocardial infarction
    Comparator
    PBS injection
    Outcome group
    Heart function · Cardiovascular

    Measurements

    Ejection fraction change
    7%
    3 d

    Source sentences

    Summary
    Magnetic resonance imaging (MRI) revealed that the microvascular grafts effectively preserved contractile performance 3 d and 6 wk after myocardial infarction, attenuated left ventricular dilation, and decreased infarct size as compared to infarcted rats treated with PBS injection as a control (3 d…
    1 context sentence
    Summary · context
    We present use of a synthetic, injectable matrix metalloproteinase (MMP)-responsive, bioactive hydrogel as an in situ forming scaffold to deliver thymosin β4 (Tβ4), a pro-angiogenic and pro-survival factor, along with vascular cells derived from human embryonic stem cells (hESC) in ischemic injuries…

    In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).

  2. 02AnimalNot a test of Thymosin beta-4 (human) aloneAnimal study (in vivo)Efficacy outcome

    In rats with myocardial infarction, microvascular grafts (hydrogel with thymosin beta‑4 and hESC-derived vascular cells) raised ejection fraction by about 12% at 6 weeks versus PBS.

    In plain wordsIn rats with a heart attack, a gel with thymosin beta‑4 and human stem cell-derived cells improved heart pumping versus PBS at 6 weeks.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    IncreaseEjection fraction at 6 weeks
    Study

    ratn: not reported in source

    rat model of myocardial infarction
    Comparator
    PBS injection
    Outcome group
    Heart function · Cardiovascular

    Measurements

    Ejection fraction change
    12%
    6 wk

    Source sentences

    Summary
    Magnetic resonance imaging (MRI) revealed that the microvascular grafts effectively preserved contractile performance 3 d and 6 wk after myocardial infarction, attenuated left ventricular dilation, and decreased infarct size as compared to infarcted rats treated with PBS injection as a control (3 d…
    1 context sentence
    Summary · context
    We present use of a synthetic, injectable matrix metalloproteinase (MMP)-responsive, bioactive hydrogel as an in situ forming scaffold to deliver thymosin β4 (Tβ4), a pro-angiogenic and pro-survival factor, along with vascular cells derived from human embryonic stem cells (hESC) in ischemic injuries…

    In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).

  3. 03AnimalNot a test of Thymosin beta-4 (human) aloneAnimal study (in vivo)Efficacy outcome

    In rats with myocardial infarction, microvascular grafts (hydrogel with thymosin beta‑4 and hESC-derived vascular cells) attenuated left ventricular dilation versus PBS.

    In plain wordsIn rats with a heart attack, a gel with thymosin beta‑4 and human stem cell-derived cells reduced heart enlargement versus PBS.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    DecreaseLeft ventricular dilation
    Study

    ratn: not reported in source

    rat model of myocardial infarction
    Comparator
    PBS injection
    Outcome group
    Heart function · Cardiovascular

    Source sentences

    Summary
    Magnetic resonance imaging (MRI) revealed that the microvascular grafts effectively preserved contractile performance 3 d and 6 wk after myocardial infarction, attenuated left ventricular dilation, and decreased infarct size as compared to infarcted rats treated with PBS injection as a control (3 d…
    1 context sentence
    Summary · context
    We present use of a synthetic, injectable matrix metalloproteinase (MMP)-responsive, bioactive hydrogel as an in situ forming scaffold to deliver thymosin β4 (Tβ4), a pro-angiogenic and pro-survival factor, along with vascular cells derived from human embryonic stem cells (hESC) in ischemic injuries…

    In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).

  4. 04AnimalNot a test of Thymosin beta-4 (human) aloneAnimal study (in vivo)Efficacy outcome

    In rats with myocardial infarction, microvascular grafts (hydrogel with thymosin beta‑4 and hESC-derived vascular cells) decreased infarct size versus PBS.

    In plain wordsIn rats with a heart attack, a gel with thymosin beta‑4 and human stem cell-derived cells shrank the damaged area versus PBS.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    DecreaseInfarct size
    Study

    ratn: not reported in source

    rat model of myocardial infarction
    Comparator
    PBS injection
    Outcome group
    Heart function · Cardiovascular

    Source sentences

    Summary
    Magnetic resonance imaging (MRI) revealed that the microvascular grafts effectively preserved contractile performance 3 d and 6 wk after myocardial infarction, attenuated left ventricular dilation, and decreased infarct size as compared to infarcted rats treated with PBS injection as a control (3 d…
    1 context sentence
    Summary · context
    We present use of a synthetic, injectable matrix metalloproteinase (MMP)-responsive, bioactive hydrogel as an in situ forming scaffold to deliver thymosin β4 (Tβ4), a pro-angiogenic and pro-survival factor, along with vascular cells derived from human embryonic stem cells (hESC) in ischemic injuries…

    In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).

  5. 05AnimalNot a test of Thymosin beta-4 (human) aloneAnimal study (in vivo)Efficacy outcome

    In rats with myocardial infarction, vessel density was elevated after treatment with the hydrogel containing thymosin beta‑4 and hESC-derived vascular cells.

    In plain wordsIn rats with a heart attack, treatment with a gel with thymosin beta‑4 and human stem cell-derived cells raised blood vessel density.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    IncreaseVessel density
    Study

    ratn: not reported in source

    rat model of myocardial infarction
    Comparator
    PBS injection
    Outcome group
    Heart function · Cardiovascular

    Source sentences

    Summary
    Elevation in vessel density was observed in response to treatment
    1 context sentence
    Summary · context
    We present use of a synthetic, injectable matrix metalloproteinase (MMP)-responsive, bioactive hydrogel as an in situ forming scaffold to deliver thymosin β4 (Tβ4), a pro-angiogenic and pro-survival factor, along with vascular cells derived from human embryonic stem cells (hESC) in ischemic injuries…

    In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).

  6. 06AnimalNot a test of Thymosin beta-4 (human) aloneAnimal study (in vivo)Mechanism

    In rats with myocardial infarction, the hydrogel with thymosin beta‑4 and hESC-derived vascular cells was linked to elevated human-derived EGF, VEGF and HGF at 1 day.

    In plain wordsIn rats with a heart attack, a gel with thymosin beta‑4 and human stem cell-derived cells came with higher human growth factors at 1 day.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    IncreaseHuman donor-derived cytokines EGF, VEGF and HGF at 1 day
    Study

    ratn: not reported in source

    rat model of myocardial infarction
    Comparator
    PBS injection
    Outcome group
    Receptor activity and mechanism · Cardiovascular

    Source sentences

    Summary
    which may be due in part to elevations in human (donor)-derived cytokines EGF, VEGF and HGF (1 d).
    1 context sentence
    Summary · context
    We present use of a synthetic, injectable matrix metalloproteinase (MMP)-responsive, bioactive hydrogel as an in situ forming scaffold to deliver thymosin β4 (Tβ4), a pro-angiogenic and pro-survival factor, along with vascular cells derived from human embryonic stem cells (hESC) in ischemic injuries…

    In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 01:52 UTC

    Study results updated

  2. Version 1

    12 Oct 2026, 18:17 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.